NCT04816526: Phase 2 - Descartes-08 anti-BCMA-CAR-mRNA-transf. auto CD8+ T cells Consolidation MRD+
NCT04910568: Phase 1b - Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04973605: Phase 1/2: BGB-11417 in Monotherapy and With Carfilzomib-dex in RRMM and t(11;14)
NCT04975997: Phase 3: IberDd Versus DVd in Participants With Relapsed Refractory Myeloma - EXCALIBER
NCT04975399: Phase 1: Study to Evaluate the Safety and Tolerability of CC-92328 in Participants RRMM
NCT04960579: Phase 1: P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Multiple Myeloma
NCT04942067: Phase 1/2: APG-2575 in Combination With Novel Therapeutic Regimens in RRMM Myeloma
NCT04775550: Phase 2: DARA RVD For High Risk SMM (PRISM)
NCT04939844: Phase 2: REST - Replacing Steroids in the Transplant Ineligble (REST)
NCT04843579: Phase 2: Selinexor in Combination With Clarithromycin, Pom & Dex RRMM - ClaSPd
NCT04802356: Phase 2: Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma
NCT04935580: Phase 1/2: Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients
NCT04879043: Phase 1/2: Study to Assess Safety of HDP-101 in Patients With RRMM
Expanded Access Protocol for Receiving Idecabtagene Vicleucel That is Nonconforming for commercial
NCT04891809: Phase 2 - Isatuximab in Combination With Rd Compared to Rd in Elderly NDMM
NCT04835129: Phase 2: Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in RRMM (IMPEDE)
NCT04824794: Phase 1/2: GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies
NCT04754945: Phase 1: Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis
NCT04786028: Phase 2 - A Study of Isatuximab Added to Standard CyBorD Induction & Lenalidomide Maint